Tiziana reports positive Phase 2a data for intranasal foralumab in na-SPMS
Tiziana Life Sciences reported positive topline results from its Phase 2a INFORM-MS trial of intranasal foralumab in non-active secondary progressive multiple sclerosis on November 9, 2026. The 12-week study showed a statistically significant reduction in microglial activation at the 50 µg dose and clinically meaningful fatigue improvements at both tested doses. The findings were consistent with longer-term observations from the company's expanded-access program, including disability stabilization and improvement.
Why it matters
The data provide placebo-controlled clinical and imaging signals for foralumab in a patient population with limited treatment options. Tiziana expects to complete the INFORM-MS analysis, discuss next steps with the FDA, and continue advancing the program.
Key facts
- 1The 50 µg treatment arm had 19 patients and produced a statistically significant reduction in microglial activation versus placebo, with p=0.0168. finanznachrichten.de
- 2After 12 weeks, MFIS scores improved by -6.17 points in the 50 µg arm, with p=0.035. finanznachrichten.de
- 3After 12 weeks, MFIS scores improved by -7.18 points in the 100 µg arm, with p=0.040. finanznachrichten.de
- 4The ongoing expanded-access program included 14 patients, with some receiving treatment for up to three years. finanznachrichten.de
- 5In the earlier expanded-access group, all 10 patients stabilized on EDSS scores and three of four patients treated continuously for 12 months improved on EDSS. finanznachrichten.de
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.